ACTIVITY DESCRIPTION/STATEMENT OF NEED

In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs).

TARGET AUDIENCE

This activity has been designed to meet the educational needs of vascular medicine specialists, pulmonologists, hematologist-oncologists, emergency medicine physicians, family medicine physicians, internal medicine physicians, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with or at risk for VTE.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

    • Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE
    • Assess the quality and validity of the evidence collected as part of real-world studies comparing the DOACs with warfarin in patients with VTE (eg, efficacy, safety, cost-effectiveness, quality of life)
    • Incorporate RWE into clinical decision-making for patients with VTE to design individualized treatment plans, especially for patients who may not be well represented in randomized clinical trials

ACCREDITATION

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is developed in collaboration with our educational partners PVI, PeerView Institute for Medical Education, and the North American Thrombosis Forum.

SUPPORT

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

RELEASE AND EXPIRATION DATES: March 23, 2021 – March 22, 2022

FACULTY DISCLOSURES AND COI

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. No one else in a position to control content has any financial relationships to disclose.

CME Advisory Committee Disclosure

Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/

Chair
Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC
Department of Haematological Medicine
Guy’s and St Thomas’ Hospitals NHS Foundation Trust
King’s College London
London, England, United Kingdom

Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Ltd; Applied Clinical Intelligence LLC; ALEXION PHARMA UK LTD; Aplagon Ltd; Bayer plc; Boehringer Ingelheim Limited; Bristol Myers Squibb; Boston Scientific Corporation; CSL Behring; Daiichi-Sankyo UK Ltd.; EmstoPA Ltd; GLG Pharma, LLC; Guidepoint Global UK Ltd.; Gulf Coast Consortia; Johnson & Johnson Medical Limited; Leo Pharma UK; Lifeblood; LifeSciences Consulting; McKinsey & Company; Medscape; Navigant Europe Limited; Pfizer Limited; Portola Pharma UK Limited; Sanofi; Takeda UK Ltd.; Temasek International Pte Ltd; Total CME; TRN – The Research Network Ltd; UK Department of Health; UK Government Health Select Committee; and UK National Health Service; and Windrose Consulting Group.
 
Other Financial or Material Support as payments for lectures, for preparation of reports, and for development of educational presentations from Aspen; Bayer plc; Boehringer Ingelheim Limited; Bristol Myers Squibb; Daiichi-Sankyo UK Ltd.; GlaxoSmithKline; Johnson & Johnson Medical Limited; Medscape; Pfizer Limited; and Portola Pharma UK Limited. Founder of The Coalition to Prevent Venous Thromboembolism.
 

CME Content Reviewer
Michael Marchick, MD
Co-Clerkship Director
Clinical Associate Professor
Department of Emergency Medicine
University of Florida College of Medicine

Michael Marchick, MD, has no financial interest/relationship or affiliation in relation to this activity.

CPE Content Reviewer
Shelley Chun, PharmD, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee Disclosures

Planning Committee Disclosures
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the CPE accredited provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity.

Angela McIntosh, PhD 
PVI, PeerView Institute for Medical Education 
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas, MPH
PVI, PeerView Institute for Medical Education 
Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of: Consultant for Fresenius Medical Care North America. 

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Donald J. DiPette, MD, FACP, FAHA
Stacy L. Sims, MSN, RN, CMCN
Jorge García, MS, MHA, MBA, FACHE

Generic Disclosure Statement

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

INSTRUCTIONS FOR ACTIVITY COMPLETION

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CPE credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

Media: Enduring Material
Release and Expiration Dates: March 23, 2021 – March 22, 2022
Time to Complete: 30 minutes